Biomatics Capital Partners, L.P. - 16 Jun 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: 10%+ Owner
Signature: /s/ Julie Sunderland, Managing Member of Biomatics Capital Management, L.L.C., the general partner of Biomatics Capital Partners, LP.
Issuer symbol: VERV
Transactions as of: 16 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 16 Jun 2021, 20:07:26 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Ownership	Footnotes
holding	VERV	Series A Preferred Stock	16 Jun 2021	Common Stock	1,535,077	Direct	F1, F2
holding	VERV	Series A-2 Preferred Stock	16 Jun 2021	Common Stock	973,734	Direct	F1, F2
holding	VERV	Series B Preferred Stock	16 Jun 2021	Common Stock	88,653	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of the Issuer's preferred stock is convertible into common stock on an approximately 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F2	These shares are held by Biomatics Capital Partners, LP ("Biomatics LP"). Biomatics Capital Management, L.L.C. ("Biomatics GP") is the general partner of Biomatics LP. Julie Sunderland and Boris Nikolic ( the "Managing Members") are the managing members of Biomatics GP. Each of the Managing Members may be deemed to share voting and dispositive power over these shares. Each of the Managing Members and Biomatics GP disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Content

Each share of the Issuer's preferred stock is convertible into common stock on an approximately 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

These shares are held by Biomatics Capital Partners, LP ("Biomatics LP"). Biomatics Capital Management, L.L.C. ("Biomatics GP") is the general partner of Biomatics LP. Julie Sunderland and Boris Nikolic ( the "Managing Members") are the managing members of Biomatics GP. Each of the Managing Members may be deemed to share voting and dispositive power over these shares. Each of the Managing Members and Biomatics GP disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.